SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending due to renewed interest in privacy coins and speculation around its upcoming halving event, with some community members suggesting it could outperform Bitcoin. Discussions highlight its limited supply and potential as a hedge against broader market volatility. Some believe it could even rival Bitcoin's dominance due to its privacy features.

FuelCell Energy, Inc. engages in the business of developing, designing, producing, constructing, and servicing high temperature fuel cells for clean electric power generation. It operates through the following geographical segments: the United States, South Korea, and Europe. The company was founded by Bernard Baker and Martin G. Klein in 1969 and is headquartered in Danbury, CT.

Fuelcell Energy Inc

FuelCell Energy is trending due to potential synergies with ExxonMobil, specifically in carbon capture technology for data centers, sparking community excitement. The community is closely monitoring the potential impact of these collaborations, especially after ExxonMobil's conference call and the surge in volume late in the day. The focus remains on whether FCEL's technology will be instrumental in ExxonMobil's carbon capture initiatives, given their past partnership and the increasing demand for clean energy solutions.

Rolls-Royce Holdings Plc designs, develops, manufactures, and services integrated power systems for use in the air, on land, and at sea. The company operates its business through following segments: Civil Aerospace, Power Systems, Defense and New Markets. The Civil Aerospace segment offers commercial aero engines and aftermarket services. The Power Systems segment includes engines, power systems and nuclear systems for civil power generation. The Defense segment consists of military aero engines, naval engines, submarines and aftermarket services. The New Markets segment includes development, manufacture and sales of small modular reactors (SMRs) and new electrical power solutions. The company was founded in March 1906 and is headquartered in London, the United Kingdom.

Rolls-Royce Holdings Plc - ADR

Rolls-Royce Holding PLC (ADR)

Rolls-Royce is trending as the community discusses recent Airbus deliveries and a substantial Vietjet Air engine order. Investor sentiment is largely positive, with some anticipating new SMR orders and analysts revising forecasts upwards. Discussions also include the potential for Rolls-Royce to power new data centers and collaborate on future aircraft engine projects.

Propy is a decentralized real-estate market place backed by superior blockchain infrastructure to facilitate real-time unified transaction in order to reduce fraud and redundancy. Propy is the world’s first international real-estate marketplace.

Propy

Propy ($PRO) is trending amidst fluctuating price action, leading to mixed sentiments within the community. Discussions revolve around identifying potential entry points, with some traders expressing frustration over recent price movements and questioning the project's short-term potential, while others remain optimistic about Propy's long-term vision in real estate tokenization and RWA.

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co.

DIS is trending amid discussions around recent price hikes for its streaming services and the integration of Hulu into Disney+, impacting subscriber counts and revenue strategies. Community members are debating the influence of political controversies and potential shifts in content strategy, while analysts weigh in on the stock's long-term growth potential and ongoing volatility. There's also buzz around the possibility of mergers and acquisitions and some debate about the quality and quantity of content available on the platform.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

SRPT is trending as investors anticipate clarity on Elevidys rollout and updated guidance during the upcoming earnings call, with specific attention to patient volume and non-ambulatory progress. The community is speculating on FDA clarity, potential global rollout, and the possibility of beating top and bottom line expectations, while also weighing milestone payments and one-time charges impacting near-term profits. Overall, investors are focused on management's tone and execution to restore trust and potentially unlock significant upside.

Devon Energy Corp. engages in the exploration, development, and production of oil and natural gas properties. It develops and operates Delaware Basin, Eagle Ford, Heavy Oil, Barnett Shale, STACK, and Rockies Oil. The company was founded by J. Larry Nichols and John W. Nichols in 1971 and is headquartered in Oklahoma City, OK.

Devon Energy Corp.

Devon Energy is trending as traders weigh the impact of OPEC+'s decision on production levels and potential acquisition scenarios for the company. Community discussions revolve around whether the stock is undervalued and poised for a breakout, or if it will remain range-bound without a buyout. Bullish investors highlight the company's financial strength and potential for long-term growth, while others express frustration with its recent performance.

Solid Power, Inc. engages in the manufacture and supply of power batteries. The firm develops all solid state battery cell technology that replaces the liquid or gel polymer electrolyte used in conventional lithium-ion battery cells with a sulfide-based solid electrolyte. It focuses on the development and commercialization of all solid state battery cells and solid electrolyte materials, primarily for the battery-powered electric vehicle market. The company was founded on August 3, 2011 and is headquartered in Louisville, CO.

Solid Power Inc

Solid Power is trending due to Vanguard's recent disclosure of a significant stake in the company, signaling institutional confidence in its long-term potential. Community discussions revolve around the implications of this investment, especially alongside existing partnerships with Samsung and BMW, and the overall prospects for solid-state battery technology. Despite some skepticism regarding the stage of commercialization, investors are closely watching SLDP as a key player in the evolving EV battery landscape.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

LEU is trending amid renewed interest in nuclear energy and uranium, especially with discussions around government support and potential deals. Community members are actively discussing the stock's technicals, potential for a short squeeze given its low float, and long-term growth prospects related to AI-driven data center power needs. A recent analyst upgrade and positive industry outlook are also contributing to the heightened interest.

Celestica, Inc. engages in the provision of supply chain solutions globally to equipment manufacturers and service providers. It operates through the following segments: Advanced Technology Solutions (ATS), and Connectivity and Cloud Solutions (CCS). The Advanced Technology Solutions (ATS) segment includes aerospace and defense, industrial, smart energy, health tech, and capital equipment businesses. The Connectivity and Cloud Solutions (CCS) segment consists of enterprise communications, telecommunications, servers, and storage businesses. The company was founded in 1994 and is headquartered in Toronto, Canada.

Celestica, Inc. - Ordinary Shares (Subordinate Voting)

Celestica, Inc.

Celestica is trending due to a Goldman Sachs upgrade and positive sentiment around its role in AI infrastructure, with many viewing it as a potential long-term growth play like Nvidia. The community is actively discussing price targets, potential earnings beats, and the company's exposure to the growing AI data center market. Some investors are taking profits after the recent surge, while others see any dip as a buying opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that five posters will be presented in collaboration with independent investigators highlighting new data on LUPKYNIS (voclosporin) at the...

Aurinia Pharmaceuticals on Monday pushed back on criticism of its lupus drug Lupkynis (voclosporin) by a top FDA official who had raised questions about the medicine’s clinical benefit in a LinkedIn post that has since been deleted.Shares of Aurinia tumbled 16% to $11.06, marking their worst day since February 2024, before recovering 4% in after-hours trading to $11.51.In a statement, Aurinia reiterated its positive outlook for Lupkynis, stating that it has an established benefit–risk profile. Aurinia highlighted that the drug was granted full FDA approval in January 2021 following the AURORA 1 study, and received additional approval in April 2024 based on data from the AURORA 2 study, which demonstrated its efficacy and safety over a three-year period.The selloff followed a post by George Tidmarsh, director of the FDA’s drug center, who said Lupkynis “has not been shown to provide a direct clinical benefit for patients.” His comments were part of a broader discussion about the agency’s use of surrogate endpoints, which are biological measures used to accelerate drug approvals, that he said had led to both “notable successes and failures.”The post drew widespread attention not only for its criticism of a specific drug and company, something regulators almost never do publicly, but also for its choice of platform.&nbsp;Soon after media reports surfaced, Tidmarsh deleted the post and clarified that his comments were “personal views” that “do not reflect those of the FDA or HHS,”&nbsp; adding that all official communications would continue to be made through formal agency channels.On Stocktwits, retail sentiment for Aurinia was ‘extremely bullish’ amid a&nbsp;whopping 10,040% surge in 24-hour message volume.One user said the stock’s decline wasn’t surprising, describing it as a healthy pullback after a strong run that could set up the next move higher.<stembedurl>https://stocktwits.com/Itsagame999/message/630423873</stembedurl>Other users expressed frustration with the company’s response, saying they had expected a stronger reaction and were disappointed by what they described as a brief, generic statement, with one adding they had lost $70,000 on the drop.<stembedurl>https://stocktwits.com/timfris/message/630421172</stembedurl><stembedurl>https://stocktwits.com/Dallas9/message/630420635</stembedurl><a href="https://stocktwits.com/symbol/AUPH">Aurinia’s stock</a> has risen 23.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Aurinia’s stock (AUPH) has risen 23.2% so far in 2025. (Photo credit: Getty Images)

Aurinia Pharma Stands By Lupus Drug After FDA Official’s Retracted Post Sparks 16% Selloff — Retail Stays Bullish On Recovery

The company reiterated its confidence in Lupkynis’ long-term efficacy and safety following its approval and the submission of supplementary data.

Equity

Aurinia (AUPH) Upgraded to Buy: Here's What You Should Know

Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of -5.88% and +10.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options

Investors need to pay close attention to AUPH stock based on the movements in the options market lately.

Retail chatter around Aurinia Pharmaceuticals picked up pace late Sunday, with investors eyeing an update on the company’s early-stage AUR200 trial targeting autoimmune conditions later in the day.The experimental therapy, first dosed in healthy volunteers in September 2024, is being evaluated in a single ascending dose study.&nbsp;The program is assessing safety, tolerability, drug behavior in the body, and biomarker response.&nbsp;AUR200 works by targeting both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand), proteins involved in immune system regulation.&nbsp;The company has said it plans to pursue one broader indication and one rare disease, both with relatively few existing treatments.&nbsp;Funding for development is coming from Aurinia’s current cash flow.In May,&nbsp;<a href="https://stocktwits.com/symbol/AUPH">Aurinia</a> reported new findings from its Phase 3 AURORA 1 study of Lupkynis (voclosporin), its approved treatment for lupus nephritis.&nbsp;The post-hoc analysis suggested&nbsp;that patients receiving triple therapy with Lupkynis, mycophenolate mofetil (MMF), and low-dose steroids achieved better proteinuria outcomes than those on MMF and steroids alone.&nbsp;&nbsp;Adverse event rates were comparable between groups.On Stocktwits, retail sentiment for <a href="https://stocktwits.com/symbol/AUPH">Aurinia Pharmaceuticals</a> was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said they wouldn’t be selling even if the stock hit $10, saying they were “in it for the big bucks.”&nbsp;<stembedurl>https://stocktwits.com/RedBarnCannabis/message/619401660</stembedurl>Another pointed out that historically, strong data has moved the stock significantly and stated that with Aurinia’s sizable cash reserves, dilution concerns were minimal, adding that they were hoping for double-digit gains following the update.<stembedurl>https://stocktwits.com/timfris/message/619390483</stembedurl>The stock has declined 1.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Bulls Charge Into Aurinia Pharmaceuticals Ahead Of Autoimmune Trial Results

AUR200 targets both BAFF and APRIL, which are key immune system proteins. It is being developed for one large indication and one rare disease.

Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?

Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?

Company News for May 13, 2025

Shares of Aurinia Pharmaceuticals Inc. (AUPH) surged 3% in premarket trading on Monday after the company’s first-quarter (Q1) earnings topped Wall Street expectations.The biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250512965572/en/Aurinia-Pharmaceuticals-Reports-Financial-Results-for-the-Three-Months-Ended-March-31-2025">reported</a> a 24% year-on-year (YoY) jump in its first-quarter (Q1) total revenue to $62.5 million, surpassing an analyst estimate of $61.06 million, according to Finchat data.The surge in revenue was primarily driven by a 25% YoY jump in net product sales of Lupkynis, the company’s FDA-approved oral therapy for treating adult patients with active lupus nephritis, to $60 million.For the three months ending March 31, 2025, the company reported a net income of $23.3 million, compared to a loss of $10.7 million in 2024.Diluted earnings per share came in at $0.16 for the quarter, compared to a loss of $0.07 per share recorded in the corresponding period of 2024, and above an analyst estimate of $0.1. &nbsp;&nbsp;&nbsp;&nbsp;Aurinia ended the quarter with cash, cash equivalents, restricted cash, and investments of $312.9 million, compared to $358.5 million on Dec. 31, 2024.CEO Peter Greenleaf said the company looks forward to a “strong performance” in 2025.The firm also reiterated its full-year total revenue guidance of $250 million to $260 million and net product sales guidance of $240 million to $250 million.On Stocktwits, retail sentiment around Aurinia jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:632/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_12_at_7_28_54_AM_png_b95ef3aeed.webp" alt="AUPH's Sentiment Meter and Message Volume as of 7:30 a.m. ET on May 12, 2025 | Source: Stocktwits" width="632" height="60"><figcaption>AUPH's Sentiment Meter and Message Volume as of 7:30 a.m. ET on May 12, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/AUPH">AUPH stock</a> is down by about 9% this year but up by over 59% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/expedia-retail-traders-remain-optimistic-despite-q1-revenue-miss/chiNeqjRbme">Expedia Retail Traders Remain Optimistic Despite Q1 Revenue Miss Ahead Of Holiday Travel Season</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Aurinia Stock Rallies On Upbeat Q1 Earnings, CEO Expects Strong Performance in 2025: Retail Sentiment Brightens

The company also reiterated its full-year total revenue guidance of $250 million to $260 million and net product sales guidance of $240 million to $250 million.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

AUPH
Aurinia Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AUPH News

AUPHAurinia Pharmaceuticals Inc